GE HealthCare Technologies Inc. (NASDAQ:GEHC) Stock Holdings Lifted by Sanibel Captiva Trust Company Inc.

Sanibel Captiva Trust Company Inc. lifted its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 139.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,484 shares of the company's stock after purchasing an additional 4,364 shares during the period. Sanibel Captiva Trust Company Inc.'s holdings in GE HealthCare Technologies were worth $585,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the company. Mercer Global Advisors Inc. ADV lifted its holdings in GE HealthCare Technologies by 15.7% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 24,326 shares of the company's stock worth $1,931,000 after buying an additional 3,303 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in GE HealthCare Technologies by 7.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,405 shares of the company's stock worth $187,000 after purchasing an additional 171 shares during the last quarter. Public Employees Retirement Association of Colorado boosted its holdings in GE HealthCare Technologies by 0.7% in the second quarter. Public Employees Retirement Association of Colorado now owns 58,894 shares of the company's stock worth $4,589,000 after purchasing an additional 408 shares during the period. AE Wealth Management LLC increased its stake in GE HealthCare Technologies by 206.3% during the second quarter. AE Wealth Management LLC now owns 17,725 shares of the company's stock valued at $1,381,000 after purchasing an additional 11,938 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ raised its holdings in shares of GE HealthCare Technologies by 7.7% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 89,251 shares of the company's stock worth $6,954,000 after purchasing an additional 6,400 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Roland Rott sold 3,577 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the sale, the chief executive officer now owns 24,298 shares in the company, valued at approximately $2,101,291.04. This represents a 12.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.27% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Jefferies Financial Group raised shares of GE HealthCare Technologies from a "hold" rating to a "buy" rating and lifted their price target for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. Stifel Nicolaus upped their target price on GE HealthCare Technologies from $100.00 to $102.00 and gave the company a "buy" rating in a report on Monday, September 30th. Wells Fargo & Company increased their price target on GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an "overweight" rating in a research report on Thursday, October 31st. Evercore ISI boosted their price objective on GE HealthCare Technologies from $98.00 to $102.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Finally, UBS Group lowered GE HealthCare Technologies from a "neutral" rating to a "sell" rating and dropped their target price for the stock from $84.00 to $74.00 in a research report on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $96.00.

GE HealthCare Technologies Price Performance

Shares of GEHC stock traded down $0.26 during midday trading on Monday, reaching $84.74. 2,855,039 shares of the company were exchanged, compared to its average volume of 2,724,028. The company's 50 day moving average price is $81.97 and its two-hundred day moving average price is $84.48. The company has a market cap of $38.72 billion, a P/E ratio of 23.28, a PEG ratio of 2.80 and a beta of 1.11. GE HealthCare Technologies Inc. has a 12 month low of $71.31 and a 12 month high of $94.55. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.98 and a current ratio of 1.23.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last announced its earnings results on Wednesday, October 30th. The company reported $1.14 EPS for the quarter, topping the consensus estimate of $1.06 by $0.08. The firm had revenue of $4.86 billion for the quarter, compared to analysts' expectations of $4.87 billion. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The firm's quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.99 earnings per share. On average, sell-side analysts expect that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current year.

GE HealthCare Technologies Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Tuesday, January 14th will be issued a dividend of $0.035 per share. This is a positive change from GE HealthCare Technologies's previous quarterly dividend of $0.03. This represents a $0.14 dividend on an annualized basis and a yield of 0.17%. The ex-dividend date is Tuesday, January 14th. GE HealthCare Technologies's payout ratio is presently 3.30%.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.